OcuLearning › Retina

Stargardt Disease (Fundus Flavimaculatus)

CHRONIC — Retina

Symptoms

  • central vision loss: progressive decline in childhood or early adulthood (ages 10–20)
  • "malingerer" pitfall: vision is often 20/100+ while the fundus still looks near-normal
  • reading difficulty: letters disappear or become blurry (central scotoma)
  • color vision changes: subtle difficulty distinguishing hues as the fovea atrophies
  • light sensitivity: discomfort in bright environments (photophobia)

Clinical Findings

Classic clinical triad

  • pisciform flecks: yellow-white "fish-tail" spots at the RPE level in the posterior pole
  • beaten-bronze macula: a dull, metallic, mottled sheen at the fovea (earliest sign)
  • bull’s-eye maculopathy: a ring of RPE atrophy around a central foveal island

Diagnostic imaging

  • "silent choroid" (ivfa): excess lipofuscin blocks the choroidal flush, creating a dark background
  • faf (autofluorescence): flecks are hyperautofluorescent; atrophy is hypoautofluorescent
  • oct: loss of the ellipsoid zone and outer nuclear layer at the fovea

Electrophysiology

  • erg: typically normal early on (unlike cone dystrophy), confirming it is a macular disease
  • eog: often subnormal (reduced Arden ratio); indicates widespread RPE dysfunction

Etiology

Genetics & pathophysiology

  • inheritance: primarily autosomal recessive (ABCA4 gene mutation)
  • mechanism: defective "flippase" protein prevents clearance of vitamin A byproducts
  • toxic buildup: accumulation of lipofuscin (A2E) in the RPE leads to cell death
  • fundus flavimaculatus: a later-onset variant with widespread flecks and slower vision loss

Red Flags

  • vitamin a warning: strictly avoid megadose vitamin a or AREDS; it accelerates A2E buildup
  • rapid decline: if vision drops significantly, assess for secondary choroidal neovascularization
  • family screening: siblings of an affected child have a 25% risk of having the disease
  • blue light: theoretical risk of accelerating damage; UV-blocking lenses are recommended

Investigations

Primary workup

  • genetic testing: sequencing the abca4 gene is the definitive diagnostic step
  • fundus autofluorescence (faf): the most sensitive non-invasive tool for monitoring flecks
  • widefield fa: look for the pathognomonic "midnight fundus" (silent choroid)

Functional testing

  • amsler grid: to monitor for central scotoma and metamorphopsia
  • goldmann visual field: to check for central scotomata and peripheral preservation

Treatment

Management strategy

  • observation: no currently approved treatment to reverse or stop the disease
  • protective: use UV-blocking tinted sunglasses (yellow/amber) to reduce phototoxicity
  • medical avoidance: ensure the patient is NOT taking AREDS-type multivitamins

Emerging therapies

  • clinical trials: deuterated vitamin A (ALK-001), gene therapy, and stem cell research
  • visual rehab: eccentric viewing training to use the "para-foveal" retina for reading

Clinical Pearl

A "beaten-bronze" fovea with peripheral pisciform flecks in an adolescent is Stargardt — ABCA4 is the gene, and vitamin A supplementation may accelerate disease, so avoid it.

Differential Diagnosis

  • • cone dystrophy (abnormal ERG, different inheritance)
  • • chloroquine toxicity (history of Plaquenil use, similar bull’s-eye appearance)
  • • best disease (autosomal dominant, distinct "egg-yolk" lesion, abnormal EOG)
  • • fundus albipunctatus (night blindness, stationary flecks, normal vision)

Related Retina Conditions